Skip to content
Malta's world news feed Local perspective with global outlook
CDE.NEWS The Dispatch
Coronavirus

Antiviral remdesivir reported as effective in limiting disease progression in monkeys with COVID-19

epa08369978 Two municipality workers pose for a photo, for the international solidarity campaign named 'One World. One Heart', in front of the Romanian Parliament Building in Bucharest, Romania, 17 April 2020. Over 40 international visual artists have been invited to create 3D animations which are simultaneously projected on the facades of buildings from all over the world. EPA-EFE/ROBERT GHEMENT

US government scientists reported Friday that the antiviral drug remdesivir was effective in treating monkeys infected with COVID-19.

“Early treatment with the experimental antiviral drug remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2, the coronavirus that causes COVID-19,” said a press release from the National Institutes of Health, which ran the experiment.

The current study of remdesivir, a drug developed by Gilead Sciences Inc. and NIAID-supported investigators, involved two groups of six rhesus macaques. One group of monkeys received remdesivir and the other animals served as an untreated comparison group. Scientists infected both groups with SARS-CoV-2.

Twelve hours later the treatment group received a dose of remdesivir intravenously, and then received a daily intravenous booster dose thereafter for the next six days. The scientists timed the initial treatment to occur shortly before the virus reached its highest level in the animals’ lungs.

Twelve hours after the initial treatment, the scientists examined all animals and found the six treated animals in significantly better health than the untreated group, a trend that continued during the seven-day study. They report that one of the six treated animals showed mild breathing difficulty, whereas all six of the untreated animals showed rapid and difficult breathing. The amount of virus found in the lungs was significantly lower in the treatment group compared to the untreated group, and SARS-CoV-2 caused less damage to the lungs in treated animals than in untreated animals.

The investigators note that the data supports initiating remdesivir treatment in COVID-19 patients as early as possible to achieve maximum treatment effect. The authors, from NIAID’s Rocky Mountain Laboratories in Hamilton, Montana, also note that while remdesivir helped prevent pneumonia, it did not reduce virus shedding by the animals. “This finding is of great significance for patient management, where a clinical improvement should not be interpreted as a lack of infectiousness,” they write.

Remdesivir works against the COVID-19 by adding mutations that ultimately destroy the virus.

 

More from Coronavirus

More →